Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston
Omeros Corporation (OMER)
Last omeros corporation earnings: 3/2 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.omeros.com
Company Research
Source: Business Wire
-- GPR174 Deficiency Improves Outcomes in Animal Tumor Models -- SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency enhances anti-tumor immune responses in animals.The studies were conducted in mouse models of melanoma and of colon carcinoma, each of which was modified to partially deplete regulatory T cells, a subset of immunosuppressive T cells. Partial depletion of regulatory T cells in mice creates a T-cell composition more similar to that in humans. GPR174 deficiency in these mice resulted in significantly reduced tumor growth and improved survival of the animals (p=0.006 in melanoma; p=0.03 in colon cancer) versus normal mice.These findings are being presented today by Marc Gavin, Ph.D., Omeros’ Director of Immunology, at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts.The presentati
Show less
Read more
Impact Snapshot
Event Time:
OMER
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OMER alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OMER alerts
High impacting Omeros Corporation news events
Weekly update
A roundup of the hottest topics
OMER
News
- Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem MeetingsBusiness Wire
- Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program [Yahoo! Finance]Yahoo! Finance
- Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access ProgramBusiness Wire
- Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.MarketBeat
OMER
Earnings
- 5/15/24 - Miss
OMER
Sec Filings
- 1/16/25 - Form 8-K
- 12/19/24 - Form 8-K
- OMER's page on the SEC website